Navigation Links
Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Date:11/7/2007

hird) showed a statistically significant reduction in cigarettes smoked over the full 12 months compared to placebo (p<0.022):

* Using a repeated measures model, vaccinated smokers who failed to quit

but showed a high antibody response smoked a median of only 10

cigarettes per day while in the study, compared to their own baseline

values of 20 cigarettes per day before treatment.

Safety Trends Continue - NicVAX(R) Shows No Compensatory Smoking, No Increased Withdrawal

Importantly, there was no evidence of compensatory smoking or increase in withdrawal symptoms observed in NicVAX(R) patients at any stage of the 12- month trial. NicVAX(R) continued to be well-tolerated with the placebo and NicVAX(R) dose groups showing comparable adverse event profiles at each stage of the clinical study.

"We are excited and greatly encouraged by the significant learning which has come from this first efficacy trial of NicVAX." said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi. "It is important to note that we have seen success in each of the critical parameters of this trial; we know the dimensions of the therapeutic antibody window which will drive continuous abstinence out to a full year, we know the relationship between the psychological and biochemical drives to quit and remain abstinent and, most importantly, we believe we now have the insight to drive a higher rate of response. We will use these encouraging final data to advance our NicVAX partnership discussions and to determine the optimal design for the next step in our clinical trial efforts for this important primary care product candidate."

About the Phase 2b Study

The Phase 2b study was a double-blind, placebo-controlled and dose-ranging study comprised of 301 patients designed to establish proof of concept and the optimal dose for the Phase 3 program. This study was designed in collaboration with the U.S. Food and Drug Administra
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
(Date:4/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5jt68c/global_api_market ) has ... 2018" report to their offering. Global API ... the Global API industry is expected to grow at a ... been divided into four major geographies which comprise Americas, ... the rest of the world. For every region, a current ...
(Date:4/21/2015)... MENLO PARK, Calif. , April 21, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative medicine, ... patients with acute myelogenous leukemia (AML) from the Phase ... cell cancer vaccine, AST-VAC1, has been selected for an ... Oncology (ASCO) Annual Meeting, to be held in ...
Breaking Medicine Technology:Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5Global API Market Outlook Report 2014-2018 2Global API Market Outlook Report 2014-2018 3Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3
... , ... Albemarle Corporation (NYSE: ALB ), a leading global ... PharmaCore to provide manufacturing capabilities for customers with projects that require ... alliance allows a seamless technology transfer from PharmaCore to Albemarle ...
... , ... Systems, Inc. today announced full integration between AVImark veterinary software ... the two-way connection allows diagnostic test requisitions and patient data ... any AVImark workstation in a veterinary practice. Test results are ...
Cached Medicine Technology:Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 2Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 3Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 4Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 5McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 2McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 3McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 4
(Date:4/21/2015)... The American Society for Dermatologic Surgery is ... Brandt, M.D., by setting up two memorial funds in ... 1982, died earlier this month at age 65 at ... opportunities for ASDS members, industry and any interested donors ... Brandt held so dear. , “Dr. Brandt was one ...
(Date:4/21/2015)... 2015 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced its ... American Payroll Association (APA) as well as NetSuite’s ... has been the nation’s payroll authority since 1982, ... and recertification credits. Held at the MGA Grand ...
(Date:4/21/2015)... Saint Louis, MO (PRWEB) April 21, 2015 ... April 29, 2015 from 5:00 to 8:00 pm at the ... Center Drive, Chapel Hill, NC 27599. More than 50 hospitals, ... across the country. All specialties will be represented. Attendees will ... Thompson, Director of Career Fairs for PracticeMatch says ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... eSight is the only technology in the world that helps ... May 5th, Low Vision Specialists of Maryland and Virginia ... unveiling and demonstration of the technology at 8:30 a.m at ... be the first ophthalmic practice in Maryland to offer the ... be available on the day of the unveiling. , How ...
Breaking Medicine News(10 mins):Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 3Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Study Reveals the Most Common Reasons Why Total Hip ... thousands of patients undergo total hip replacement surgery in ... disease and other related hip problems. According to ... of The Journal of Bone and Joint Surgery ...
... Jan. 2 Joan Lunden, the nation,s,longest-running morning ... two decades. During her tenure she reported ... two Royal weddings. One of the most,visible ... of her career to,educating Americans about health and ...
... ATLANTA, Jan. 2 Publix, Procter & Gamble, and,Special ... people with,intellectual disabilities achieve their dreams. Now they,re ... Special Olympics. , 1. Support ... by,purchasing your favorite P&G products like Tide, Pampers, Bounty ...
... tips on how to avoid injury while performing winter ... snow from your driveway and sidewalks can be physically ... proper health and safety precautions, says the American Academy ... than 118,000 people were treated in U.S. hospital emergency ...
... keep colds and flu at bay , , FRIDAY, Jan. 2 ... there,s one tidbit that doctors stand by as the best way ... free of germs is one of the simplest and most effective ... other infectious disease, experts say. , "Disease transmission is hand-to-hand combat, ...
... Va.In a study to determine the diagnostic value of ... cancer, researchers were able for the first time to ... and normal residual thyroid tissue directly after surgery. , ... an article in the January issue of The ...
Cached Medicine News:Health News:Replacing Your Total Hip Replacement 2Health News:Replacing Your Total Hip Replacement 3Health News:Joan Lunden Inks Three-Year Deal to Host Health Corner(R) Television Series 2Health News:'Be A Fan' of Special Olympics Throughout January 2Health News:Shovel Snow Safely 2Health News:To Protect Yourself, Wash Those Germs Away 2Health News:To Protect Yourself, Wash Those Germs Away 3Health News:To Protect Yourself, Wash Those Germs Away 4Health News:Molecular imaging enables earlier, individualized treatment of thyroid cancer 2
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
Medicine Products: